JERUSALEM, March 13 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. , an Israel based company, is proud to announce its 1 year anniversary and accomplishments.
CEO Nadav Kidron states, “Over the past year we have hit many great milestones for our supporting shareholders including surpassing the International Review Board and Ministry of Health approvals to further our initial flagship product, oral insulin, toward human clinical trials. In addition, we were able to gain the support of Swiss Caps, one of the largest manufacturers of soft gel capsules in the world, to accept us as a client and to support our company with their validation of our technology in producing our capsules for a direct share exchange in lieu of a cash payment.
Between the end of 2006 and the beginning of 2007, we approached and succeeded in building an internationally known scientific board, containing very strong contacts within the NIH (National Institution of Health), ADA (American Diabetes Association), Hadassah Research Hospital, and many other well-known institutions both professional and educational. Their expertise expands within Endocrinology, Immunology, Diabetes and Medicinal practices globally, with strengths in greater Europe, South Africa, and North America
This has enabled us to further our horizons and focus on innovations in medicinal research. Within our first year, Oramed is in the process of registering I.P. over another method of Insulin delivery. In addition, we have begun pre clinical testing on an oral replacement for the highly demanded flu vaccine, with over a billion doses disseminated annually, as reported by the CDC.
We are pragmatically enhancing our pipeline to incorporate new technologies to help take the pinch out of life for many suffering patients with debilitating diseases as well as enable a larger percentage of the population to take necessary vaccinations and maintain a healthier lifestyle.
We look forward to another strong year of developments and expansion as we move forward with great hope.
For more information on Oramed Pharmaceuticals please visit our website: www.oramedpharma.com
Legal Notice Regarding Forward-Looking Statements
This news release contains statements, which may constitute “forward- looking statements”. Those statements include statements regarding the intent, belief or current expectations of Oramed Pharmaceutical Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that Oramed is in the process of registering I.P. over another method of Insulin delivery; that we have begun pre clinical testing on an oral replacement for the highly demanded flu vaccine, with over a billion doses disseminated annually; that we are enhancing our pipeline to incorporate new technologies to help take the pinch out of life for many suffering patients with debilitating diseases as well as enable a larger percentage of the population to take necessary vaccinations and maintain a healthier lifestyle; and that we hope to have another strong year of developments and expansion.. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; we may be unable to raise funds and resources to pursue research and development; our patent applications may not be accepted by the patent office; we may be unable to successfully defend our patents from infringement by third parties, there is a risk that our patents may be subsequently shown to be invalid or infringe the patents of others, our products may never gain FDA or other regulatory body approval for human consumption and we may be unable to successfully commercialize our future products. Readers should refer to our most recent period reports filed on Edgar.
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252 info@oramedpharma.comwww.oramedpharma.com
Oramed Pharmaceuticals, Inc.
CONTACT: Investor Relations Contact - Vinisha Agnihotri, OramedPharmaceuticals, Inc., +1-646-467-2252, info@oramedpharma.com
Web site: http://www.oramedpharma.com/
